These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 9853189)

  • 1. The role of third-generation beta-blocking agents in chronic heart failure.
    Bristow MR; Roden RL; Lowes BD; Gilbert EM; Eichhorn EJ
    Clin Cardiol; 1998 Dec; 21(12 Suppl 1):I3-13. PubMed ID: 9853189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sympathetic activation and the role of beta-blockers in chronic heart failure.
    Krum H
    Aust N Z J Med; 1999 Jun; 29(3):418-27. PubMed ID: 10868514
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carvedilol in heart failure.
    Kelly DT
    Cardiology; 1993; 82 Suppl 3():45-9. PubMed ID: 8106165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative hemodynamic, left ventricular functional, and antiadrenergic effects of chronic treatment with metoprolol versus carvedilol in the failing heart.
    Gilbert EM; Abraham WT; Olsen S; Hattler B; White M; Mealy P; Larrabee P; Bristow MR
    Circulation; 1996 Dec; 94(11):2817-25. PubMed ID: 8941107
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term oral carvedilol in chronic heart failure.
    Di Lenarda A; Sabbadini G; Moretti M; Sinagra G
    Expert Opin Pharmacother; 2004 Jun; 5(6):1359-72. PubMed ID: 15163280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Second- and third-generation beta-blocking drugs in chronic heart failure.
    Bristow MR; Abraham WT; Yoshikawa T; White M; Hattler BG; Crisman TS; Lowes BD; Robertson AD; Larrabee P; Gilbert EM
    Cardiovasc Drugs Ther; 1997 May; 11 Suppl 1():291-6. PubMed ID: 9211023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-adrenergic blockade in the treatment of congestive heart failure.
    Denbow CE
    West Indian Med J; 2000 Jun; 49(2):102-7. PubMed ID: 10948844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction.
    Frishman WH; Henderson LS; Lukas MA
    Vasc Health Risk Manag; 2008; 4(6):1387-400. PubMed ID: 19337551
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beta-blockers in heart failure. The 'new wave' of clinical trials.
    Krum H
    Drugs; 1999 Aug; 58(2):203-10. PubMed ID: 10473016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-blocker treatment of chronic heart failure: comparison of carvedilol and metoprolol.
    Maack C; Elter T; Böhm M
    Congest Heart Fail; 2003; 9(5):263-70. PubMed ID: 14564145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carvedilol in the treatment of chronic heart failure.
    Moe G
    Expert Opin Pharmacother; 2001 May; 2(5):831-43. PubMed ID: 11336626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Carvedilol. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy.
    McTavish D; Campoli-Richards D; Sorkin EM
    Drugs; 1993 Feb; 45(2):232-58. PubMed ID: 7681374
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of carvedilol in congestive heart failure secondary to coronary artery disease.
    Das Gupta P; Broadhurst P; Raftery EB; Lahiri A
    Am J Cardiol; 1990 Nov; 66(15):1118-23. PubMed ID: 1977300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta-blockers in congestive heart failure: the pharmacology of carvedilol, a vasodilating beta-blocker and antioxidant, and its therapeutic utility in congestive heart failure.
    Feuerstein G; Ruffolo RR
    Adv Pharmacol; 1998; 42():611-5. PubMed ID: 9327976
    [No Abstract]   [Full Text] [Related]  

  • 15. [Carvedilol in cardiac decompensation].
    Dib J
    Rev Med Liege; 1996 Feb; 51(2):198-200. PubMed ID: 8650455
    [No Abstract]   [Full Text] [Related]  

  • 16. Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure.
    Mortara A; La Rovere MT; Pinna GD; Maestri R; Capomolla S; Cobelli F
    J Am Coll Cardiol; 2000 Nov; 36(5):1612-8. PubMed ID: 11079666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Commentary on the Carvedilol or Metoprolol European Trial (COMET).
    Poole-Wilson PA
    Am J Cardiol; 2004 May; 93(9A):40B-2B. PubMed ID: 15144936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale, design, and methods for a Coreg (carvedilol) Heart Failure Registry (COHERE). COHERE Participant Physicians.
    Franciosa JA; Abraham WT; Fowler M; Gilbert EM; Greenberg B; Massie BM; Chen T; Lukas MA; Nelson JJ
    J Card Fail; 2000 Sep; 6(3):264-71. PubMed ID: 10997754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vasodilatory action of carvedilol.
    Sponer G; Strein K; Bartsch W; Müller-Beckmann B
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S5-11. PubMed ID: 1378150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.
    Krum H; Sackner-Bernstein JD; Goldsmith RL; Kukin ML; Schwartz B; Penn J; Medina N; Yushak M; Horn E; Katz SD
    Circulation; 1995 Sep; 92(6):1499-506. PubMed ID: 7664433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.